Resume

Sign in

Project Research

Location:
Montreal, Quebec, Canada
Posted:
October 15, 2016

Contact this candidate

BOBY MAKABI-PANZU

*** **********, ***********, *** ***

acw2or@r.postjobfree.com

*-514-***-****

Personal Profile

Bilingual French-English professional with strong educational background in Biochemistry, Pharmacology, Immunology and Virology and extensive work experience in designing, developing and leading projects aimed at characterizing, testing and evaluating vaccines and vaccine adjuvant systems using clinical samples and humanized animal models; Advanced expertise in immunoassay, molecular technique, virology method and cell-based assay development; Accomplished in generating and applying new protocols and technologies; Significant work experience in regulated environments; Strong problem-solving with critical thinking and decision-making ability; Excellent both written and oral communication and interpersonal relationships skills; Offering broad range of transferable skills; Seeking a suitable role which will prove to be both a personal and professional challenge.

Key technical Skills

Hands-on experience in clinical and animal sample analysis and development of cell-based assays (e.g. cytokine bioassays, ELISPOT, LPA and multi-color flow cytometry based CBA, CFSE, ICS, dimer/tetramer and CD107 assays) and immunoassays (e.g. ELISA etc…) with good knowledge of new ligand-binding approaches (e.g. BIACORE, Octet, Luminex and MSD based technologies).

Proficiency in using flow cytometry software, including DIVA, FCS express, Cell Quest and FlowJo for data acquisition and/or analysis, MS Office Suite and statistical software, such as Prism and Statview, for data analysis, report and/or presentation, coupled with strong aptitudes for managing bioscience projects.

In-depth knowledge of GCP, GLP, GCLP and GMP guidelines, US/European Pharmacopoeia standards and drug/biologic development processes from discovery to marketing authorisation stage following the applicable local regulation (HPFB, CFR FDA, MHRA or EMEA).

Advanced expertise in mammalian cell cultures (e.g. cultures of PBMC, T cell subsets, B cells and monocytes, dendritic cell or macrophage differentiation from monocytes and cell transfection etc..) with significant working experience with human and animal virus and mouse study models (e.g. wild-type and humanized mice) in BSL-2 and 3 containment facilities.

Strong abilities in virus culture, titration and detection by ELISA, plaque assay or qRT-PCR, testing of nAb by PRNT or VNT, nucleic acid extraction, purification and analysis using Nanodrop, gel electrophoresis, Northern blot, PCR, and protein isolation, purification and analysis using liquid chromatography, SDS-PAGE, Western Blot with extensive training experiences in DNA recombinant technology and sequencing.

Significant experiences in designing, formulating, preparing and characterizing lipid nanoparticle-based carriers (e.g. liposomes, archaeosomes, oil emulsions etc…), for physico-chemical properties (e.g. shape, size, zeta potentials, pyrogenicity, purity, sterility and physical stability), in vitro cellular uptake and toxicity, in vivo disposition and immune adjuvant activities using cultured mammalian cells and/or rodent models.

Education and Qualifications

2006: PGC in Biomedical Sciences - University of Westminster - London (United of Kingdom)

2004 Certificate in Clinical Research Monitoring - Krieger Research Centre Inc (CRO) - Ontario (Canada)

1995: PhD degree in Microbiology-Immunology - Faculty of Medicine, Laval University - Quebec (Canada)

1990: MS degree in Molecular and Cellular Biology - Faculty of Medicine, Laval University - Quebec (Canada)

1987: BS degree in Biological Sciences - Faculty of Sciences, Laval University - Quebec (Canada)

Employment and Training History

02/2012 – 02/2015: Research Scientist In Vaccinology - Pirbright Institute - Surrey

Project: Development of a heterologous prime-boost vaccination strategy combining live attenuated vaccine, BRSV SH vaccine versus subunit recombinant human RSV protein-based vaccine in calves with maternal antibodies.

Participating in the design of the study protocol and experimental schedule, logistic planning and conduct of regulated experimental manipulations on calves, including intranasal priming with the live attenuated vaccine (BRSV SH vaccine), intramuscular boosting with the subunit vaccine (recombinant human RSV protein-based vaccine), aerosol challenge with a wild-type virulent BRSV isolate (Snook) and nasopharyngeal swab and blood sample collection, assisted by the PI and animal facility technicians.

Independently managing all other assigned projects and related research activities, including processing samples collected from animals; blood for serum and PBMC preparation and nasopharyngeal swabs for nasal secretion preparation.

Developing relevant bio-analytical methods to analyze harvested samples, encompassing Flow cytometry and ELISPOT based virus neutralizing test (VNT) and ELISA to examine blood serum and nasal secretion samples for neutralizing antibodies and antibody isotyping, B ELISPOT and Flow cytometry-based cell phenotyping and functional assays to analyse PBMC samples, for plasma B cells and functional T cells, and qRT-PCR and plaque assays to monitor virus load in nasal secretions samples.

Carrying out cultures of a variety of cells, including cultures of PBMC, IgG-secreting B cell hybridoma, Vero, CEF, FCK and MDBK cells and propagation, titration and storage (liquid nitrogen or -80oC) of viruses (e.g. BRSV snook isolate and wild type and recombinant Fowlpox (FPV) virus expressing BRSV antigens) in permissive cells (e.g. MDBK, Vero, FCK or CEF cells).

Preparing BRSV and FPV antigens from constituted stocks for ELISA testing and gamma-delta T cell-depleted PBMC by use of magnetic beads for FCM-based intracellular cytokine staining (ICS) assays.

Quality controlling results before report in lab meetings and/or scientific conferences and publication in peer-reviewed journal articles and/or patenting.

Undertaking background literature searches and reviewing research data to maintain advanced scientific expertise and foster better understanding and interpretation of project planned activities and expected outputs.

Keeping accurate written and records of research data and stored laboratory stocks in the laboratory database system and carrying out production of documents such as protocols, internal procedures, SOPs, grant abstracts and article manuscripts.

Maintaining collaborative relationships with colleagues, technical staff, group leaders, pharmaceutical representatives, and key partners.

Proposing new research ideas in light of new technologies relevant for the project and the Institute’s interest research areas and supporting the Institute high-level events and meetings related to the science innovation and promotion.

02/2014-05/2015- Trainee in GCP - Whitehall Training, Brook House - Surrey

Professional development (refresher) web-based training in Good Clinical Practices (GCP)

09/2007-02/2012: Senior Research Associate In Immunology - Center for Molecular Medicine and Immunology – Immunomedics Inc – Morris Plains, New Jersey, United States

Project: Development of poxvirus subunit vaccines from immunoconjugates of poxvirus antigen-derived peptides and HLA-DR targeting antibodies with clinical samples from smallpox-vaccinated donors

Designing multi-epitopic synthetic peptides from sequences of poxvirus antigens (e.g. WR, NYVAC, Lister, Copenhagen, Wyeth Dryvax, NYCBOH etc…) retrieved from public database like GenBank.

Recruiting smallpox vaccinated human donors after written informed consent, for blood collection, processing and storage (Liquid nitrogen).

Designing, developing, and optimising methods required for use in the project, which included SSP-PCR, ELISA, PRNT, ELISPOT, multi-color flow cytometry CFSE based cell assays and cell cultures for poxvirus propagation and titration.

Conducting tests of new peptide epitope candidates with donor sera for detection of specific antibodies including neutralizing antibodies using ELISA and PRNT respectively, and donor PBMC for recognition by donor T cells, using ELISPOT and flow cytometry-based CFSE-based cell assays, after HLA typing by SSP-PCR.

Selecting and chemically conjugating peptide candidates, which were recognized by donor sera and PBMCs, to HLA-DR-targeting antibodies and evaluating in HLA-DR-matching transgenic mice for induction of antibody production in serum, by ELISA and PRNT, and T cell responses in spleens, by flow cytometry CFSE-based cell assays.

Collecting, analysing and quality controlling all the data for report in internal meetings with the higher management and presentation in external conferences and submission in peer-reviewed journals.

Writing experimental plans, protocols, SOPs and manuscripts and maintaining written records of data and lab stock and equipment inventory.

Identifying emerging technologies of great relevance for the project and proposing new project ideas for grant writing purposes.

Supervising a laboratory staff and collaboratively working with colleagues, technical staff, the PI and other researchers.

09/2005-07/2006: PGC Trainee In Biomedical Sciences - University of Westminster, London

Professional Development Training in Molecular Diagnostics, Molecular Therapeutics and Recombinant DNA technology.

11/2004-09/2007: Special Leave or absence due to Family Sickness

02/2002-11/2004: Research Fellow In Immunology - Hospital for Sick Children, the Research Institute, Toronto, Ontario, Canada

Project: Identification and characterization of HIV antigen-derived HLA class I-restricted peptide epitopes with use of clinical HIV-infected samples

Designing, by use of web-accessible in silico approaches, new HIV antigen-derived HLA class I-restricted peptide sequences.

Ex-vivo testing the newly designed peptide sequences by ELISPOT and Flow cytometry-based methods in HLA-typed PBMCs, isolated through Ficoll-hypaque gradient from healthy and HIV-infected donor blood samples, or splenocytes from HLA class I-matching transgenic mice spleens infected with a lab Influenza virus A strains (PR8 or X-31) grown in embryonated eggs and titrated by hemagglutination assay (HA).

Developing a model of NODSCID mice as alternative for in vivo study of HIV infections.

Mentoring graduated and undergraduate students on concepts related to immunology and vaccinology.

Undertaking data quality control and background literature searches necessary to ensure adequate and accurate interpretations of research project outputs.

06/2003-01/2004: Clinical Trial Monitoring Trainee - Krieger Research Center, Toronto, Ontario, Canada

Training for clinical trial conduct in accordance with the study protocol, ICH-GCP guidelines and applicable regulations (e.g HPFB, MHRA, EMEA or FDA).

Attending internships in clinical trial essential document design (e.g. protocols, informed consent forms, investigator brochures, advertisements for subject recruitment, case report forms (CRF)) and tracking of CRF data for completeness, accuracy, consistency with source documents, and adverse event (AEs).

Additional Employment and Training History

01/2000-02/2002: Research Consultant In Vaccinology - University of Montreal, Faculty of Veterinary Medicine, Quebec, Canada

01/2000-02/2002: Pgc Trainee In Applied Informatics - Laval University, Faculty of Engineering and Sciences, Quebec, Canada

10/1999-01/2000: Technical Support InRetrovirology - Canadian Food Inspection Agency, Saint-Hyacinthe, Quebec, Canada

01/1999-10/1999: Researcher In Immunology - University of Pennsylvania/Wistar Institute, Philadelphia, Pennsylvania, USA

05/1997-01/1999: Research Scientist In Vaccinology - University of Montreal/BIOMED Laboratories Inc., Montreal, Québec, Canada

04/1995-04/1997: Research Associate In Immunology - National Research Council, IBS, Ottawa, Ontario, Canada

Affiliation, License & Professional Development

Life-time Membership of British Society of Immunology (ID25682)

Home Office license for conducting experiments with animals

Professional development courses in Management and problem-solving skills

Publications and Communications

Boby Makabi-Panzu, Jean- Francois Elouet, Sabine. Riffault, Sara Hägglund, Krister Blodörn, John Pringle, Michelle Thom, Jean-Francois Valarcher& Geraldine Taylor (2014) Kinetics and antibody isotype profile in calves intranasally primed with bovine respiratory virus lacking the SH gene (BRSVΔSH): Effects of parenteral boosting with human (H)RSV proteins and implications in protection against BRSV, Immunol 143:77

Sara Hägglund, Kefei Hu, Krister Blodörn, Boby Makabi-Panzu, Karin Ellencrona, Mike Thorpe, Karin Lövgren-Bengtsson, Sabine Riffault, Geraldine Taylor, Jean-Francois Valarcher and Jean-François Eléouët (2014) Characterization of an experimental vaccine for bovine respiratory syncytial virus; Clin. Vaccine Immunol 21:997

KristerBlodörn, Sara Hägglund, Jenna Fix, Catherine Dubuquoy, Boby Makabi-Panzu, Michelle Thom, Per Karlsson, Jean-Louis Roque, Erika Karlstam, John Pringle, Jean-François Eléouët, Sabine Riffault, Geraldine Taylor, and Jean-Francois Valarcher (2014) Safety and efficacy evaluations of BRSV with deletion of the gene SH and human recombinant N protein nanorings in calves with maternal antibodies. PLoS One 9:e100392.

KristerBlodorn, S. Hagglund, J. Fix, C. Dubuquoy, B. Makabi-Panzu, M. Thom, J.L. Roque, E. Karlstam, J.Pringle, J.F. Eleouet, S. Riffault, G. Taylor and J.F. Valarcher Protective efficacy induced by a live, attenuated rBRSV vaccine and a subunit vaccine containing P, M2-1 and N-nanorings displaying epitopes of F and G, against BRSV in calves (2013). RSV vaccines for the World, October 14-16, Porto, Portugal

Taylor, Alice P; Makabi-Panzu, Boby; Chen, Xiaochuan; Gold, David V; Goldenberg, David M (2012). Evaluation of a non-viral vaccine in smallpox-vaccinated individuals and immunized HLA-transgenic mice, Hum immunol 73: 612

Alice P. Taylor, Boby Makabi-Panzu, David Goldenberg (2010). Immunoconjugates comprising poxvirus-derived peptides and antibody against antigen-presenting cells for subunit-based poxvirus vaccines (US Patent application 12/915,515).

Alice P. Taylor, Boby Makabi-Panzu, Mike X. Chen, and David M. Goldenberg (2010). Studies in the development of an alternative smallpox vaccine. NBC Sixth Annual Meeting, Mohonk Mountain House, New Paltz, NY.

Boby Makabi-Panzu, Mike X. Chen, Alice P. Taylor and David M. Goldenberg (2009). Immune responses to a novel HLA-DR antibody-conjugated poxvirus interleukin-18 binding protein-derived peptide in HLA-DR04 transgenic mice. DoD NorthEast Conference, Columbia University, New York, November 11

Youssef Elazhary, Boby Makabi-Panzu, David John Hurley, Sylvette Laurent (2004) Delivery system for entrapping macromolecules and a method for preparing same. Hong Kong Intellectual property Journal 66: 1-192

Sprott, G. Dennis, Patel, Girishchandra B., Makabi-Panzu, Boby, Tolson, Douglas L. (2004) Archaeosomes, archaeosomes containing coenzyme Q.sub.10, and other types of liposomes containing coenzyme Q.sub.10 as adjuvants and as delivery vehicles (Canadian Patent 2,247,241).

Boby Makabi-Panzu, Youssef Elazhary, David Hurley, Sylvette Laurent (2003). New method and delivery system for entrapping charged macromolecule and preparation of same (Canadian Patent 2,426,967).

Youssef Elazhary, Boby Makabi-Panzu, David Hurley, Sylvette Laurent (2003). New method and delivery system for entrapping charged macromolecule and preparation of same (US Patent 6,552,004).

Sprott, G. Dennis, Patel, Girishchandra B., Makabi-Panzu, Boby, Tolson, Douglas L. (2002) Archaeosomes, archaeosomes containing coenzyme Q.sub.10, and other types of liposomes containing coenzyme Q.sub.10 as adjuvants and as delivery vehicles (US Patent 6,403,117).

GD Sprott, GB Patel, B Makabi-Panzu, DL Tolson (2000). For vaccine formulations as adjuvants and/or delivery systems, to enhance immune response to immunogens in animal such as human. (US Patent 6,132,789).

Omri A, Makabi-Panzu B, Agnew BJ, Sprott GD, Patel GB (2000) Influence of coenzyme Q10 on tissue distribution of archaeosomes, and pegylatedarchaeosomes, administered to mice by oral and intravenous routes. J. Drug Target 7(5) 383-392.

Harpin, S., B. Makabi-Panzu, D. Hurley, M. Mbikay, B. Talbot, Y. ElAzhary. (1999). Vaccination of cattle with a DNA plasmid encoding the bovine viral diarrhea virus major glycoprotein E2. IBC Genetics Vaccines Conference.

Boby Makabi-Panzu, André Désormeaux, Pierrette Gourde and Michel Bergeron (1998). Serum and intracellular stability of liposomal dideoxycytidine. Effect of lipid composition. Cell. and Mol. Biol. 44: 277-284.

Makabi-Panzu, B., Patel G.B., and Sprott, G.D. (1998). Coenzyme Q10 in vesicles composed of archaeal ether lipids or conventional lipids enhances the immuno-adjuvanticity to encapsulated protein .Vaccines 16: 1504-1509.

Serge Harpin, Boby Makabi-Panzu, David J. Hurley, MajambuMbikay, Brian Talbot, and Youssef Elazhary (1998). Vaccination of Cattle with DNA Plasmid encoding the Bovine Viral Diarrhoea Virus major Glycoproteins E2. IBC's 4th Annual Genetic Vaccines and Immunotherapeutic Strategies. Washington, DC, October 25-27.

Hurley, D.J., S. Harpin, B. Makabi-Panzu, B.G. Talbot, M. Mbikay, Y. ElAzhary. 1998. Development of humoral, mucosal and cell mediated immunity and protection against viral challenge following vaccination of cattle with a plasmic containing the E2 gene of bovine viral diarrhea virus. R.A. Moore Biostress Research Poster Day.

Boby Makabi, Celine Lessard, Denis Beauchamps, Andre Desormeaux, Louise Poulin, Michel Tremblay, and Michel G. Bergeron (1995). Saturable and nonsaturable components of uptake of liposomal dideoxycytidine by RAW 264.7 cells, a three step process. J. ACQ. IMMUNE DEFIC. SYND. 8 : 227-235.

B. Makabi-Panzu, C. Lessard, S. Perron, A. Desormeaux, M. Tremblay, L. Poulin, and M.G. Bergeron (1994). Comparison of Anti-Human immunodeficiency virus activity, cellular accumulation, and tissue distribution of free and liposomal dideoxycytidine. AIDS RES. HUM. RETROV. II: 1463-1470.

André Désormeaux, Pierrot Harvie, Boby Makabi-Panzu, Sylvie Perron, Denis Beauchamps, Michel Tremblay, Louise Poulin and Michel Bergeron (1994). Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated dideoxycytidine. AIDS 8: 1545-1553.



Contact this candidate